Sterling Bancorp (NASDAQ:SBT) reported quarterly losses of $(0.04) per share. This is a 157.14 percent decrease over earnings of $0.07 per share from the same period last year.
Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $18
Oppenheimer analyst Mark Breidenbach maintains Seres Therapeutics (NASDAQ:MCRB) with a Outperform and lowers the price target from $36 to $18.